Biotech Support Group Helps Drive Innovation to Expand Proteomic Biomarkers Through a Full Range of Albumin & IgG Removal Products

Tuesday, May 28, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Biotech Support Group reveals LC-MS focus on research & development on their Albumin Removal & IgG Products.

MONMOUTH JUNCTION, N.J., May 28, 2019 /PRNewswire-PRWeb/ -- Biotech Support Group (BSG), a leading provider of proteomic

sample prep and enrichment products and services, reveals LC-MS focus on research and development on their Albumin Removal Products as highlighted on their new webpage,

Driving innovation through cost effective and efficient sample prep methods, BSG's base of Albumin & IgG Removal Products are essential for expanding proteomic biomarkers into routine healthcare. With a LC-MS knowledgebase of over 1000 serum proteins, they are equipped to support targeted and quantitative protein biomarkers from blood, serum or plasma.

Dr. Swapan Roy, Ph.D., President and Founder of Biotech Support Group, states, "With biomarker research at our core, we understand all the sample prep challenges of serum proteomics. We are the first company to really establish quantitative LC-MS bias characteristics of not only proteome separations but also digest conditions. So we think our knowledgebase will be extremely helpful to assist our customers develop the next generation of proteomic innovation."

Additionally, Biotech Support Group has recently reported on research, presented as a technical poster report and highlighted at the 26th Annual International Molecular Med TRI-CON, held March 10-15, 2019 in San Francisco, CA USA. The research shows that serum proteomic workflows can be especially challenging due to the presence of highly abundant proteins and background signal from antibody derived peptides. Consequently, researchers need ways to enrich differently. Without any requirement for immuno-affinity, BSG has developed a full range of Albumin & IgG Removal Products to overcome the challenges of clinical proteomics.

The company's most recent application report highlights the serum proteome bias characteristics of AlbuVoid™ & NuGel™ Protein A, alone or in serial combination, using LC-MS reporting metrics. The poster presentation was entitled "AlbuVoid™ Enrichment & Antibody Depletion – Tackling the Challenges of Serum Proteomics Part II", co-authored with collaborators from the Rutgers Proteomics Center. Click here to download.

Previously, Biotech Support Group has reported on a variety of tools that can bias towards or against select sub-proteomes of serum without the use of immuno-affinity. This has led to success in the company's own LC-MS discovery programs, most notably a patent pending panel of cancer serum biomarkers called Stroma Liquid Biopsy™. "After many years of optimizing our unique bead-based enrichment methods, we can offer two diverse separation strategies, either a binding or a voiding strategy. These are all consumable products suitable for all proteomic analytical platforms, from LC-MS to functional assays. We are very pleased to report these significant discoveries to help solve the challenges of serum proteomics," states Dr. Swapan Roy, Ph.D.

"Products and digest conditions produce different proteome qualitative and quantitative windows of observation. In our own discovery efforts, we have demonstrated the value for enrichment of categorical sub-proteomes to provide mechanistic insight into disease pathologies", reports Matthew Kuruc, Vice President Business Development and co-author of the report. "With a knowledgebase of over 1000 serum proteins, now we can help proteomic researchers choose the best available products and methods for their particular needs."

For more information on the BSG complete line of Albumin & IgG Removal products, click this link.

About Biotech Support Group LLC Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to

Contact: Matthew Kuruc 732-274-2866


SOURCE Biotech Support Group

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store